Met Non Small Cell Cancer Registry (MOMENT)

Study Overview
=================
Brief Summary
-----------------
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.

Detailed Description
-----------------
This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.

Official Title
-----------------
Disease Registry on Patients With Advanced NSCLC Harboring METex14 Skipping Alterations (MOMENT)

Conditions
-----------------
Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants who signed ICF Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay) Participants who are starting or are already being treated with systemic therapy Exclusion Criteria: Participants who are enrolled in a clinical trial
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Advanced Non-small Cell Lung Cancer with METex14 skipping alterations<br>Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Best Overall Response (BOR) |  | Through study completion, up to approximately 4.9 years | 
| Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 |  | Up to approximately 4.9 years | 
| Overall Survival (OS) |  | Through study completion, up to approximately 4.9 years | 
| Number of Participants with Adverse Events (AEs) |  | Up to approximately 4.9 years | 
| Number of Participants with Adverse Reactions (ARs) |  | Up to approximately 4.9 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Disease Registry, METex14 Skipping Alterations